Latest Galectin Therapeutics Inc (GALT) Headlines

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Galectin Therapeutics Inc (GALT) Headlines

Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...

Galectin Therapeutic Has Returned 98.8% Since SmarTrend Recommendation (GALT)
Comtex SmarTrend(R) - Fri Mar 07, 9:08AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 98.75% as of today's recent price of $15.90.

Today's Biggest Stories in Biotech: Galectin Therapeutics Inc, Merrimack Pharmaceuticals and Nektar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 27, 8:27AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...

Galectin Therapeutics wins US patent for GR-MD-02
M2 - Thu Feb 27, 5:22AM CST
US-based therapeutics company Galectin Therapeutics (NasdaqCM:GALT) disclosed on Wednesday the receipt of the patent for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease" in the US.

Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease
GlobeNewswire - Wed Feb 26, 7:42AM CST
Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Patent and Trademark Office issued patent number 8,658,787 to the Company for its application titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease." The patent covers the Company's carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis, providing patent protection through 2031.

Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Galectin Therapeutic Shares Up 109.5% Since SmarTrend's Buy Recommendation (GALT)
Comtex SmarTrend(R) - Tue Feb 25, 9:41AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 109.50% as of today's recent price of $16.76.

5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.

Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop
GlobeNewswire - Mon Feb 24, 9:42AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Nonalcoholic Steatohepatitis (NASH) Workshop hosted by JMP Securities on Thursday, February 27, 2014 in New York, NY. NASH, a progressive liver disease caused by the accumulation of fat in the liver leading to inflammation and fibrosis, is estimated to affect nine to 15 million people, including children, in the United States.

90.8% Return Seen to Date on SmarTrend Galectin Therapeutic Call (GALT)
Comtex SmarTrend(R) - Tue Feb 18, 9:06AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 90.75% as of today's recent price of $15.26.

Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership
ACCESSWIRE - Thu Feb 13, 10:02AM CST
A growing body of research on galectins is demonstrating the important role that this family of carbohydrate-binding proteins plays in T-cell survival, fibrosis of organs, allergies, deadly diseases like cancer, regulation of many immune responses and much more. Only defined about two decades ago, 15 different mammalian galectins have now been identified, with overexpression of specific galectins implicated in a variety of diseases. The potential of this emerging science is tremendous, to say the least, to help bridge gaps in a broad range of deadly or debilitating disorders with great unmet medical need.

Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 13, 7:00AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics, served on a panel titled "Keeping an I on Oncology: The ASCO Immunotherapy Preview" at the 16 Annual BIO CEO & Investor Conference. The panel was held February 11, 2014, in New York City.

3 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 11, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.

Shares of GALT Up 86.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 10, 9:10AM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 3 months, Galectin Therapeutic has returned 86.25% as of today's recent price of $14.90.

Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 05, 7:15AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the 16 Annual BIO CEO & Investor Conference, to be held February 10-11, 2014, at the Waldorf Astoria Hotel in New York City. The conference is hosted by the Biotechnology Industry Organization and is the largest independent investor conference focused on established and emerging publicly traded and select private biotech companies.

Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma
GlobeNewswire - Mon Feb 03, 10:30AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Food and Drug Administration (FDA) has agreed that a Phase 1B clinical trial of the galectin inhibitor GR-MD-02 in combination with Yervoy(R) (ipilimumab) in patients with metastatic melanoma may proceed. Providence Portland Medical Center, a leader in immunotherapy research and translational clinical trials in melanoma and other cancers, filed the IND in late December 2013.

Galectin Therapeutic Has Returned 71.4% Since SmarTrend Recommendation (GALT)
Comtex SmarTrend(R) - Fri Jan 31, 4:47PM CST
SmarTrend identified an Uptrend for Galectin Therapeutic (NASDAQ:GALT) on November 25th, 2013 at $8.00. In approximately 2 months, Galectin Therapeutic has returned 71.38% as of today's recent price of $13.71.

Galectin Therapeutics Inc & SBH Sciences Inc partnership establishes Galectin Sciences LLC for development of small molecule inhibitors of galectin-3
M2 - Tue Jan 28, 6:22AM CST
Therapeutic company Galectin Therapeutics Inc (NasdaqCM:GALT) and SBH Sciences Inc on Monday jointly reported the formation of collaborative joint venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration, called Galectin Sciences LLC.

Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration
GlobeNewswire - Mon Jan 27, 7:15AM CST
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, and SBH Sciences, Inc., a world leader in cell-based assays to measure biological activity and developer of cytokines, growth factors, biologics and monoclonal antibodies, jointly announce the establishment and formation of Galectin Sciences, LLC, a collaborative venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration.

Galectin Therapeutics Inc (GALT) Stock Research Links

GALT Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 113

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 83

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 211

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 252

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 197

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
TIER IV Simplifies Autonomous Driving with CARLA 1.0

Updated Category News Views 63

No More Detours in Autonomous Development Ever messed with a puzzle that just won't fit until suddenly, it clicks? That's what TIER IV just pulled off with their latest work on CARLA 1.0, the open-source simulator. There's no more mucking about with that separate Python-based bridge to get things communicating—now we're talking native Autoware support. A direct line to...

Continue Reading
Wealth Forum Puts AI and Tokenisation Before Private Wealth

Updated Category News Views 30

Private wealth is about to get squeezed from three directions at once: younger heirs, smarter machines and assets that do not fit neatly in the old family-office binder. That is the real backdrop to the Future of Wealth Forum, a new GFTN and Luxembourg House of Financial Technology partnership slated for Luxembourg City on September 27-29, 2027. It is early days,...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 16

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 213

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 50

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading

Top 5 Most Recently Viewed Articles

RAMM Pharma Corp. Strategizes Potential Sale of Canapar

Updated Category News Views 184

RAMM Pharma Corp. Explores Strategic Sale Options RAMM Pharma Corp. (CSE: RAMM), along with its wholly owned subsidiaries, is considering the sale of its subsidiary, Canapar Corp., and its industrial facility situated in Italy. This strategy aligns with the Company’s goal of enhancing operational efficiency and focusing on growth avenues in the cannabinoid industry....

Continue Reading
Marquis Software Solutions Faces Major Data Breach Issues

Updated Category News Views 206

Marquis Software Solutions Faces Data Breach Concerns Recently, Marquis Software Solutions, a notable software and services provider, faced a serious incident regarding a data breach that may have compromised the personal information of many individuals. This breach raised significant concerns for anyone whose data might have been affected. Details of the Cybersecurity...

Continue Reading
Recovering Losses: GSK Securities Class Action Explained

Updated Category News Views 192

Understanding the GSK Securities Class Action Lawsuit Investors in GSK plc (NYSE: GSK) now find themselves presented with a significant opportunity to participate in a class action lawsuit. This legal action is initiated on behalf of purchasers of American Depositary Receipts (ADRs) from a defined Class Period. The relevant dates for this lawsuit span from early in 2020...

Continue Reading
CYPFER and Michael Bay Team Up for Cybersecurity Advancements

Updated Category News Views 366

Strengthening Cybersecurity in Entertainment with CYPFER In an era where digital security is paramount, CYPFER is leading the charge to develop comprehensive cybersecurity strategies tailored for the film and entertainment industry. The company has formed a partnership with iconic filmmaker Michael Bay, known for his blockbuster hits that captivate audiences worldwide....

Continue Reading
Chris Hall Appointed as CPO of IRIS Software Group

Updated Category News Views 108

Chris Hall Steps in as Chief Product Officer at IRIS Software Group Pivotal leadership appointment will accelerate product innovation and delivery of AI-first strategy IRIS Software Group, a renowned global provider of accounting, HR, payroll, and education software, has announced a significant enhancement to its leadership team with the appointment of Chris Hall as Chief...

Continue Reading